South Korea provides both standard and next-generation biological therapies for Myasthenia Gravis. Available protocols include monoclonal antibodies like Efgartigimod and Complement C5 inhibitors. Major centers specialized in neurology utilize advanced apheresis and therapeutic plasma exchange to manage refractory cases effectively.
- Systemic therapy: MFDS-approved pyridostigmine and corticosteroids serve as primary frontline management.
- Advanced biologics: FcRn blockers including Efgartigimod and Rozanolixizumab target harmful autoantibodies.
- Targeted inhibitors: Complement C5 inhibitors like Zilucoplan are available for antibody-positive gMG.
- Surgical intervention: Thymectomy procedures are performed using robotic systems at digitalized hospitals.
Bookimed Expert Insight: Korea excels in digitalizing neurological care to prevent medical errors. Seoul National University Bundang Hospital uses the unique BESTcare system. This system tracks treatment protocols for 1,500,000 yearly patients to ensure safety during intensive therapies like plasmapheresis. Large facilities like SNUH serve over 10,000 daily patients, offering vast clinical experience in rare neuromuscular disorders.
Patient Consensus: Patients note it is important to connect with specialized neurology societies in Korea. They emphasize seeking hospitals with dedicated neuromuscular departments for the newest biological drug availability.